15 年
手机商铺
公司新闻/正文
455 人阅读发布时间:2013-10-15 10:23
| Antibodies for Pancreatic Cancer Research from GeneTex | ||||||||||||||
| Pancreatic cancer (specifically, pancreatic ductal adenocarcinoma) has proven to be a particularly stubborn foe. While the incidence and mortality of other well-known malignancies have decreased, these metrics have trended slightly upward for pancreatic cancer (Vincent et al, 2011). In addition, this cancer is so clinically insidious that four out of five patients already have advanced disease by the time they seek medical attention. Given the rather poor efficacy of systemic therapies against pancreatic cancer, the harsh reality is that more than 95% of patients will expire within five years of their initial diagnosis. | ||||||||||||||
| It is widely believed that substantive progress against this malignancy will only come from a better understanding of its basic biology. In an intriguing new paper from Marin-Muller et al, the authors describe a tumor suppressor microRNA (MiR-198) and its relationship to a set of tumorigenic factors (i.e., MSLN, OCT-2, PBX-1, and VCP) that together form a complex interactome that also involves NF-kB signaling. The researchers demonstrate how downregulation of MiR-198, frequently noted in pancreatic carcinomas, leads to upregulation of these factors and a worse prognosis. A higher MiR-198 level, in contrast, alters network expression and is associated with a better clinical outlook. Thus, this work not only identifies key players in pancreatic cancer cell biology, but also suggests new directions for prognostic marker and therapeutics research. | ||||||||||||||
| GeneTex would like to introduce some of its antibody products for detection of the protein factors described in this study. Our catalog also includes antibodies against other targets relevant to pancreatic cancer research, including SMAD4, BRCA2, TP53, KRAS, andCA19-9. | ||||||||||||||
|
||||||||||||||
|